D. E. Shaw & Co., Inc. Bellus Health Inc. Transaction History

D. E. Shaw & Co., Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$7.14 - $8.53 $2.58 Million - $3.09 Million	-361,892 Reduced 83.13%	73,421 $528,000
Q4 2022 Feb 14, 2023	SELL	$8.22 - $10.76 $1.1 Million - $1.44 Million	-133,708 Reduced 23.5%	435,313 $3.58 Million
Q3 2022 Nov 14, 2022	BUY	$8.95 - $12.0 $5.09 Million - $6.83 Million	569,021 New	569,021 $6.01 Million
Q1 2022 May 16, 2022	SELL	$5.56 - $7.99 $315,324 - $453,136	-56,713 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$5.26 - $8.3 $298,310 - $470,717	56,713 New	56,713 $457,000
Q1 2021 May 17, 2021	SELL	$3.03 - $4.58 $31,669 - $47,870	-10,452 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$2.27 - $3.3 $23,726 - $34,491	10,452 New	10,452 $32,000

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.